Carl Zeiss Meditec AG
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Andreas Pecher
- Full Time Employees
- 2,066
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- Goschwitzer Strasse 51-52 Jena Germany 07745
- IPO Date
- Aug 3, 2012
- Website
- zeiss.de
- Similar Companies
- Business
- Carl Zeiss Meditec AG, a leading medical technology company listed on the MDAX and TecDAX, develops and supplies innovative technologies and workflow solutions for ophthalmology and microsurgery. The company offers comprehensive product portfolios through its Ophthalmology strategic business unit, including diagnostic systems such as optical coherence tomography (OCT) platforms like CIRRUS AngioPlex and CLARUS 700 with indocyanine green angiography (ICGA), visualization solutions like ARTEVO 850 and ARTEVO 750 surgical microscopes, laser systems for refractive surgery including ZEISS SMILE and SMILE pro on VisuMax 800, implants and consumables for cataract and corneal refractive surgery; vitreoretinal platforms like the EVA NEXUS from DORC with subretinal injection cannulae and midfield endoillumination probes; and solutions for managing chronic eye diseases, glaucoma, retina and posterior segment disorders. Its Microsurgery strategic business unit provides visualization systems for neurosurgery, ear-nose-throat, spine surgery, plastic and reconstructive surgery, and dentistry. Founded in 2002 through the merger of ZEISS Ophthalmology with Asclepion-Meditec AG and headquartered in Jena, Germany, Carl Zeiss Meditec operates globally with subsidiaries in over 50 countries, major employee concentrations in the USA, Japan, Spain, France, India and China, and generates revenue primarily from ophthalmology serving eye care professionals worldwide. Majority-owned by Carl Zeiss AG with 41% free float, the company recently completed the acquisition of Dutch Ophthalmic Research Center (D.O.R.C.) in April 2024 to expand its retinal surgery workflow and portfolio; integrated DORC enhancements showcased at AAO 2025 including new instrument gauges, software updates for CALLISTO eye on ARTEVO platforms, and 510(k) clearances for advanced imaging; and reported revenue growth to €1,600.1 million in the first nine months of fiscal 2024/25, reflecting successful DORC consolidation and ongoing digital innovations like the AI-ready Research Data Platform.
Carl Zeiss Meditec AG (CZMWY) Q2 2026 Earnings Call Transcript
Carl Zeiss Meditec Q2 Earnings Call Highlights
Carl Zeiss Meditec AG (OTCMKTS:CZMWY) Sees Large Increase in Short Interest
Carl Zeiss Meditec: Bad Optics But With 'Buy' Potential
Carl Zeiss Meditec AG (OTCMKTS:CZMWY) Receives Average Recommendation of “Hold” from Analysts
Carl Zeiss Meditec AG (CZMWY) Q1 2026 Earnings Call Transcript
Carl Zeiss Meditec: Why This Company Is A Good Choice For 2026
Carl Zeiss Meditec AG (CZMWY) Q4 2025 Earnings Call Transcript
Carl Zeiss Meditec AG (CZMWY) Discusses CEO Transition and Management Continuity Strategy Following Code of Conduct Investigation Transcript
Carl Zeiss: The Results After 6M25 Are Encouraging For 2025-2027E
Carl Zeiss Meditec AG (CZMWF) Q2 2025 Earnings Call Transcript
Carl Zeiss Meditec: Recovery Seems Clear Enough
Carl Zeiss: Why I Am So Positive
My 3 Favorite European Stocks To Diversify Your Portfolio
Carl Zeiss: Significant Underperformance, Valuation At Multi-Year Lows
Carl Zeiss Meditec AG (CZMWF) Q3 2024 Earnings Call Transcript
Carl Zeiss Meditec: Slightly Better Valuation, Still A Significant Upside
Carl Zeiss Meditec AG (CZMWF) Q2 2024 Earnings Call Transcript
Carl Zeiss: We've Seen Outperformance, But I See More Upside Potential
Carl Zeiss Meditec AG announces agreement to acquire Dutch Ophthalmic Research Center (D.O.R.C.)